Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the ...

Discover IMRX’s innovative cancer drug atebimetinib and upcoming milestones. Learn about trial results, financial outlook, ...

FOLFIRINOX chemotherapy is feasible in selected elderly patients with pancreatic ductal adenocarcinoma, though toxicity ...

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Study Overview Revolution Medicines, Inc. is running a ...

Individuals with chronic, untreated hepatitis C virus infection may be at greater risk for pancreatic ductal adenocarcinoma, ...

Now, researchers are turning to an unexpected source for early PDAC detection: faecal samples. While analysing poo might seem ...

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using ...

Pancreatic ductal adenocarcinoma (PDAC), is highly aggressive and lethal. It is the most prevalent type of pancreatic cancer, making up 90% of cases; it also has a high rate of metastasis, with an ...

Researchers from the School of Pharmacy and Pharmaceutical Sciences recently published a paper in Molecular & Cellular Proteomics, a top international proteomics journal, describing their work in ...